Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice

Current Molecular Medicine

Volumn 13, Issue 3, 2013, Pages 446-458

  Ke, S ^a   Wang, W ^a   Qiu, X ^a,b   Zhang, F ^a,c   Yustein, J T ^a   Cameron, A G ^a   Zhang, S ^d   Yu, D ^d   Zou, C ^e   Gao, X ^e   Lin, J ^a,f   Yallampalli, S ^a   Li, M ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

CT; EGF; FDG; Her 2; Interleukin 11; MMP; Molecular imaging; Multi agent imaging; Multi modality imaging; Optical imaging; PET; RGD; SPECT

Indexed keywords

DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; GELATINASE A; GELATINASE B; INTERLEUKIN 11; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; STROMA; TUMOR VOLUME; X RAY;

EID: 84877763664     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652413805076849     Document Type: Article

References (39)

1. Muschler J, Streuli CH. Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol 2010; 2(10): a003202.
2. Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev 2011; 21(1): 80-5.
3. Saracci R, Vineis P. Environment and cancer: the legacy of Lorenzo Tomatis. Environ Health 2011; 10 Suppl 1: S1.
4. Muzi M, Mankoff DA, Link JM, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 2009; 50(8): 1267-75.
5. Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011; 32(8): 1107-21.
6. Wiechec E. Implications of genomic instability in the diagnosis and treatment of breast cancer. Expert Rev Mol Diagn 2011; 11(4): 445-53.
7. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 2011; 4(3): 255-66.
8. dos Santos RA, Teixeira AC, Mayorano MB, Carrara HH, de Andrade J, Takahashi CS. Variability in estrogenmetabolizing genes and their association with genomic instability in untreated breast cancer patients and healthy women. J Biomed Biotechnol 2011; 2011: 571-784.
9. Gemmel C, Eickhoff A, Helmstadter L, Riemann JF. Pancreatic cancer screening: state of the art. Expert Rev Gastroenterol Hepatol 2009; 3(1): 89-96.
10. Paul SR, Bennett F, Calvetti JA, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87(19): 7512-6.
11. Li C, Price JE, Milas L, et al. Antitumor activity of poly(Lglutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999; 5(4): 891-7.
12. Coons AH. Labeling Techniques in the Diagnosis of Viral Diseases. Bacteriol Rev 1964; 28: 397-9.
13. Long P. FDA Clears a Test for Ovarian Cancer: Test can help identify potential malignancies, guide surgical decisions. FDA News Release 2009 Sept 11.
14. Tchou J, Sonnad SS, Bergey MR, et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 2010; 12(6): 657-62.
15. Wang W, Ke S, Kwon S, et al. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem 2007; 18(2): 397-402.
16. Wang W, Ke S, Wang X, Charnsangavej C, Gelovani JG, Li C. Synthesis and evaluation of a new near-iInfrared fluorescence (NIRF) imaging agent targeted to matrix metalloproteinase-2. Mol Imaging 2005; 4(3): 282.
17. Auld DS, Lovell S, Thorne N, et al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci USA 2010; 107(11): 4878-83.
18. Sampath L, Kwon S, Ke S, et al. Dual-labeled trastuzumabbased imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007; 48(9): 1501-10.
19. Lewis VO, Ozawa MG, Deavers MT, et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res 2009; 69(5): 1995-9.
20. Wang W, Ke S, Wu Q, et al. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging 2004; 3(4): 343-51.
21. Wang W, Qiu X, Zhang F, et al. An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity. Contrast Media Mol Imaging 2011; 6(4): 200-8.
22. Saga T, Koizumi M, Furukawa T, Yoshikawa K, Fujibayashi Y. Molecular imaging of cancer: evaluating characters of individual cancer by PET/SPECT imaging. Cancer Sci 2009; 100(3): 375-81.
23. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5(1): 5-23.
24. Mangia A, Malfettone A, Simone G, Darvishian F. Old and new concepts in histopathological characterization of familial breast cancer. Ann Oncol 2011; 22 Suppl 1: i24-30.
25. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011; 12(5): 477-88.
26. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011; 223(2): 307-17.
27. Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815(2): 197-213.
28. Wang W, Cameron AG, Wendt JA, Mawad ME, Ke S. Multiwavelength Optical Imaging of Human Tumor Xenografts. Aust J Chem 2011; 64(5): 625-32.
29. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 2010; 7(1): 38-47.
30. Cherry SR. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med 2009; 39(5): 348-53.
31. Dehghani H, Srinivasan S, Pogue BW, Gibson A. Numerical modelling and image reconstruction in diffuse optical tomography. Philos Transact A Math Phys Eng Sci 2009; 367(1900): 3073-93.
32. Vinegoni C, Razansky D, Figueiredo JL, et al. Born normalization for fluorescence optical projection tomography for whole heart imaging. J Vis Exp 2009; (28). pii: 1389.
33. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6(10): 813-23.
34. Cabaniols JP, Mathis L, Delenda C. Targeted gene modifications in drug discovery and development. Curr Opin Pharmacol 2009; 9(5): 657-63.
35. Peltz SW, Welch EM, Jacobson A, et al. Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci USA 2009; 106(25): E64; author reply E5.
36. Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 2009; 106(9): 3585-90.
37. Mastro AM, Gay CV, Welch DR. The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis 2003; 20(3): 275-84.
38. Adams KE, Ke S, Kwon S, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 2007; 12(2): 024017.
39. Med Watch. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. FDA Drug Safety and Availability. 2010 Feb 26.